Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INCR Stock Forecast 2025-2026
$1.50
Current Price
$81.77M
Market Cap
Buy 8
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to INCR Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
INCR Price Momentum
+0.7%
1 Week Change
-6.3%
1 Month Change
-30.2%
1 Year Change
-5.7%
Year-to-Date Change
-42.7%
From 52W High of $2.62
+28.2%
From 52W Low of $1.17
📊 TOP ANALYST CALLS
Did INCR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if InterCure is one of their latest high-conviction picks.
Latest INCR Stock Price Targets & Analyst Predictions
INCR has shown a year-to-date change of -5.7% and a 1-year change of -30.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for INCR. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INCR Analyst Ratings
8
Buy
4
Hold
0
Sell
INCR Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.50
Latest INCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 12, 2023 | TD Cowen | Vivien Azer | Outperform | Maintains | $5.00 |
| Dec 11, 2017 | Barclays | Jack Meehan | Equal-Weight | Initiates | $40.00 |
| Nov 14, 2017 | Credit Suisse | Erin Wilson | Outperform | Maintains | $54.00 |
| Nov 13, 2017 | Keybanc | Donald Hooker | Overweight | Maintains | $46.00 |
| Nov 10, 2017 | Baird | Eric Coldwell | Outperform | Maintains | $46.00 |
| Aug 17, 2016 | Jefferies | Buy | Maintains | $55.00 | |
| Aug 12, 2016 | Goldman Sachs | Buy | Maintains | $62.00 | |
| Apr 18, 2016 | Avondale Partners | Market Perform | Maintains | $47.00 | |
| Sep 1, 2015 | Jefferies | Buy | Upgrade | $51.00 | |
| May 27, 2015 | Jefferies | Hold | Maintains | $37.00 | |
| Feb 12, 2015 | Baird | Outperform | Upgrade | $29.00 |
Intercure Ltd. (INCR) Competitors
The following stocks are similar to InterCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Intercure Ltd. (INCR) Financial Data
Intercure Ltd. has a market capitalization of $81.77M with a P/E ratio of 22.2x. The company generates $68.83M in trailing twelve-month revenue with a -28.4% profit margin.
Revenue growth is -23.0% quarter-over-quarter, while maintaining an operating margin of -86.8% and return on equity of -17.0%.
Valuation Metrics
Market Cap
$81.77M
Enterprise Value
$58.85M
P/E Ratio
22.2x
PEG Ratio
-1.0x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
-23.0%
Gross Margin
+31.9%
Operating Margin
-86.8%
Net Margin
-28.4%
EPS Growth
+7.5%
Financial Health
Cash/Price Ratio
+111.2%
Current Ratio
1.7x
Debt/Equity
53.2x
ROE
-17.0%
ROA
-7.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Intercure Ltd. (INCR) Business Model
About Intercure Ltd.
What They Do
Pharmaceutical company specializing in cannabis-based products.
Business Model
Intercure Ltd. generates revenue by developing, producing, and distributing a wide range of cannabis-based therapeutic and wellness products. The company leverages advanced cultivation techniques and proprietary research to create high-quality treatments, thereby establishing strategic partnerships and collaborations with global leaders in the pharmaceutical and wellness sectors to enhance its market reach.
Additional Information
Intercure's operations extend across multiple countries, positioning it as a significant player in the evolving cannabis market. The company emphasizes rigorous scientific research and regulatory compliance, actively participating in clinical studies and contributing to cannabinoid pharmacology, which supports its commitment to elevating health outcomes and advancing the acceptance of medical cannabis in mainstream healthcare.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
320
CEO
Mr. Alexander Rabinovich
Country
Israel
IPO Year
2021
Website
www.intercure.coIntercure Ltd. (INCR) Latest News & Analysis
Latest News
Quick Summary
InterCure's 2024 results will be impacted by damages from the October 7, 2023 terrorist attack on its southern facility and ongoing Gaza conflict. The company expects full compensation from Israeli authorities.
Why It Matters
The damage to InterCure's facility may impact its financial performance, while potential compensation from the Israeli authorities could offset losses, influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
InterCure Ltd. (NASDAQ: INCR) announced a corporate update on February 12, 2025. Further details regarding the announcement were not provided in the excerpt.
Why It Matters
InterCure's announcement may signal management changes or strategic shifts, impacting investor confidence and potential stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The funding for facility expansion may reach NIS 107M, with investments from CEO Alexander Rabinovich and key investors Yaron Yakobi and Tzahi Hagag becoming significant shareholders.
Why It Matters
The increase in funding to NIS 107M indicates strong shareholder confidence and potential for growth, which could enhance company stability and attract further investment.
Source: PRNewsWire
Market Sentiment:
Neutral
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
9 months ago
Quick Summary
InterCure Ltd. (INCR) demonstrated resilience in H1 2024 performance, despite facing significant challenges, as noted in equity research by Pablo Zuanic of Zuanic & Associates.
Why It Matters
InterCure Ltd.'s resilience in H1 2024 indicates strong operational management, potentially boosting investor confidence and suggesting stability amidst challenges.
Source: Benzinga
Market Sentiment:
Positive
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
9 months ago
Quick Summary
InterCure Ltd. (NASDAQ: INCR) announced its financial and operating results for the six months ending June 30, 2024, with amounts reported in New Israeli Shekels (NIS).
Why It Matters
InterCure's financial results could influence investor sentiment by revealing performance trends, impacting stock valuation and trading decisions in the cannabis sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InterCure Ltd. has partnered with Cookies to cultivate, manufacture, import, and distribute Cookies' cannabis products in 8 licensed pharmacies.
Why It Matters
InterCure's partnership with Cookies enhances its product portfolio and market reach, potentially increasing revenue and brand recognition in the growing cannabis sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About INCR Stock
What is Intercure Ltd.'s (INCR) stock forecast for 2025?
Analyst forecasts for Intercure Ltd. (INCR) are not currently available. The stock is trading at $1.50.
Is INCR stock a good investment in 2025?
According to current analyst ratings, INCR has 8 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INCR stock?
Price predictions from Wall Street analysts for INCR are not currently available. The stock is trading at $1.50.
What is Intercure Ltd.'s business model?
Intercure Ltd. generates revenue by developing, producing, and distributing a wide range of cannabis-based therapeutic and wellness products. The company leverages advanced cultivation techniques and proprietary research to create high-quality treatments, thereby establishing strategic partnerships and collaborations with global leaders in the pharmaceutical and wellness sectors to enhance its market reach.
What is the highest forecasted price for INCR Intercure Ltd.?
Price targets from Wall Street analysts for INCR are not currently available. The stock is trading at $1.50.
What is the lowest forecasted price for INCR Intercure Ltd.?
Price targets from Wall Street analysts for INCR are not currently available. The stock is trading at $1.50.
What is the overall INCR consensus from analysts for Intercure Ltd.?
The overall analyst consensus for INCR is bullish. Out of 6 Wall Street analysts, 8 rate it as Buy, 4 as Hold, and 0 as Sell.
How accurate are INCR stock price projections?
Stock price projections, including those for Intercure Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 10:55 PM UTC